ABBI Abraxis Bioscience (MM)

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced the filing of its Form 10 registration statement in connection with the proposed plan to separate its proprietary business -- Abraxis Oncology and Abraxis Research (the new Abraxis BioScience) -- from its hospital-based business -- Abraxis Pharmaceutical Products (APP). The information statement outlines the operations of the proprietary business and can be found at the SEC�s Web site under the company name �New Abraxis, Inc.� The company will apply to list the securities on the NASDAQ Global Market under the symbol �ABII.� Following is a link to the information statement on the SEC�s Web site: http://www.sec.gov/Archives/edgar/data/1409012/000119312507177626/ dex991.htm. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) About Abraxis BioScience, Inc. Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab� platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE�, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.